Schimmelpennink Evert B. — SEC Form 4 filings
SEC reporting owner CIK 1713795. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-26.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-03-25 to 2026-06-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 28,089 shares, $251,411 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: purchase of 28,089 shares @ $8.95 ($251,411) in LENZ Therapeutics, Inc., filed 2026-03-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | President, CEO and Secretary, Director | 5 | 1 leg · 28,089 sh · $251,411 | — | 9 |
| Contineum Therapeutics, Inc. (CTNM) | Director | 3 | — | — | 3 |
| iBio, Inc. (IBIO) | Director | 2 | — | — | 2 |
Form 4 filings — Schimmelpennink Evert B.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-03-30 | 4 | LENZ Therapeutics, Inc. (LENZ) | Purchase (P): 28,089 @ $8.95 | EDGAR |
| 2026-01-06 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 358,100 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | iBio, Inc. (IBIO) | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | LENZ Therapeutics, Inc. (LENZ) | Option exercise (M): 4,200 @ $1.04 · Option exercise (M): 4,200 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | iBio, Inc. (IBIO) | Grant/award (A): 18,900 (derivative) @ $0 | EDGAR |
| 2024-07-23 | 4 | LENZ Therapeutics, Inc. (LENZ) | Option exercise (M): 45,000 @ $1.04 · Option exercise (M): 45,000 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 387,106 (derivative) @ $0 · Grant/award (A): 82,723 (derivative) @ $0 · Grant/award (A): 315,864 (derivative) @ $0 · Grant/award (A): 475,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1713795 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →